

eTable 1

	After 2-dose mRNA-1273				After 3-dose mRNA-1273			
	n	Age mean (SD)	Sex women (%)	B cell (x10 <sup>9</sup> /l) <sup>1</sup> median (range)	n	Age mean (SD)	Sex women (%)	B cell (x10 <sup>9</sup> /l) <sup>2</sup> median (range)
<b>All patients</b>	161	60.2 (10)	64 (39.8)	0.10 (0.0-86.0)	129	60.1 (10.3)	53 (41.1)	0.11 (0.00-14.95)
<b>Lymphoma</b>								
During rituximab +/- chemotherapy	2	70 (6)	0 (0)	0.00 (0.00-0.00)	1	74 (0)	0 (0.0)	0.00 (0.00-0.00)
< 12 months after rituximab +/- chemotherapy	6	60 (15)	2 (33.3)	0.01 (0.00-0.04)	4	61 (17)	2 (50.0)	0.15 (0.00-0.45)
< 12 months after autologous HCT (BEAM)	7	53 (17)	4 (57.1)	0.12 (0.00-0.19)	5	50 (19)	4 (80.0)	0.22 (0.17-0.23)
<b>Multiple myeloma</b>								
1st line therapy	7	58 (9)	3 (42.9)	0.03 (0.01-0.04)	2	68 (4)	1 (50.0)	0.04 (0.01-0.08)
Daratumumab-containing therapy	28	63 (7)	12 (40.0)	0.05 (0.00-0.62)	30	63 (7)	12 (40.0)	0.04 (0.00-0.33)
IMiDs	15	60 (7)	5 (33.3)	0.10 (0.00-0.27)	14	59 (6)	5 (35.7)	0.09 (0.00-0.25)
< 9 months after autologous HCT (HDM)	13	62 (7)	4 (30.8)	0.12 (0.01-86)	10	61 (7)	3 (30.0)	0.11 (0.03-0.37)
<b>Chronic lymphocytic leukemia</b>								
Wait & see	14	63 (9)	6 (42.9)	8.31 (1.10-75.01)	12	62 (9)	5 (41.6)	7.50 (1.25-14.96)
Ibrutinib	4	58 (6)	2 (50.0)	2.08 (0.02-56.10)	1	54 (0)	1 (100.0)	na
<b>Chronic myeloid leukemia</b>								
Tyrosine kinase inhibitors	12	52 (10)	5 (41.7)	0.23 (0.14-0.50)	10	52 (10)	3 (30.0)	0.17 (0.08-0.23)
<b>Acute myeloid leukemia and high-risk MDS</b>								
Hypomethylating therapy	5	59 (22)	1 (20.0)	0.04 (0.00-0.10)	3	52 (29)	1 (33.3)	0.05 (0.00-0.07)
High-dose chemotherapy	5	64 (2)	3 (60.0)	0.06 (0.01-0.24)	4	64 (2)	3 (75.0)	0.18 (0.06-0.28)
<b>Myeloproliferative disease</b>								
Ruxolitinib	17	59 (8)	9 (52.9)	0.17 (0.05-0.59)	12	58 (11)	5 (41.6)	0.11 (0.07-0.30)
<b>Allogeneic HCT</b>								
< 6 months after HCT	12	61 (11)	5 (41.7)	0.01 (0.00-0.28)	9	65 (6)	5 (55.5)	0.19 (0.07-0.49)
Chronic GvHD	13	61 (10)	3 (23.1)	0.11 (0.00-1.09)	12	60 (10)	3 (25.0)	0.14 (0.00-0.81)
<b>CAR T cell therapy</b>								
CD19-directed	1	72	0 (0)	0.00 (0.00-0.00)	0	na	na	na

**Supplemental Table 1: Baseline characteristics of patients included in pseudovirus neutralisation analysis.** These were all patients with S1 IgG 50-300 BAU/ML and a random selection of patients with S1 IgG ≥300 BAU/ml after the standard 2-dose mRNA-1273 schedule (Haggenburg et al, Blood Advances 2022). <sup>1</sup>Absolute B cell number at time of inclusion; <sup>2</sup>absolute B cell number at time of 3rd vaccination. Na: not applicable.

eTable 2

	N	%	IgG S1 after 2 <sup>nd</sup> vaccination (BAU/ml)		
			median	25th - 75th percentile	
<b>All patients</b>	104	15.1	2323.0	529.1	5133.5
<b>Lymphoma</b>					
During R-chemo	3	7.0	0.1	0.1	
<12 months after R-chemo	3	7.7	10539.1	2812.7	
<12 months after autologous HCT (BEAM)	3	10.7	7012.2	68.1	
<b>Multiple myeloma</b>					
1st line therapy	2	8.0	38.1	20.5	
Daratumumab-containing therapy	4	8.3	1310.3	291.2	2481.5
IMiDs	8	14.8	1129.0	357.3	16229.4
<9 months after autologous HCT (HDM)	4	8.3	3278.0	1942.2	3402.5
<b>Chronic lymphocytic leukemia</b>					
Wait & see	11	20.4	2934.1	307.4	9315.9
Ibrutinib	3	8.3	748.6	319.7	
<b>Sickle cell disease</b>					
Hydrea containing therapy	31	100.0	2920.8	1760.8	5567.8
<b>Chronic Myeloid leukemia</b>					
Tyrosine kinase inhibitors	10	19.2	2252.5	1447.5	3654.2
<b>Acute myeloid leukemia and high-risk MDS</b>					
Hypomethylating therapy	0	0.0			
High-dose chemotherapie	3	14.3	2842.2	1101.2	
<b>Myeloproliferative disease</b>					
Ruxolitinib	6	16.2	1909.4	614.2	5084.5
<b>Allogenic SCT</b>					
< 6 months after HCT	1	2.0	175.8	175.8	175.8
Chronic GvHD	5	8.9	8964.6	3149.3	17534.5
<b>CAR T cell therapy</b>					
CD19-directed	7	14.0	0.1	0.1	529.1

**Supplemental Table 2: Patients who did not receive a 3<sup>rd</sup> vaccination.** From the n=723 patients included in the cohort (Haggenburg et al, Blood Adv 2022), n=104 patients did not receive a 3<sup>rd</sup> vaccination. Only patients with hematologic malignancies were prioritized per Dutch COVID-19 vaccination protocol, and sickle cell disease patients (n=31) did not receive a 3<sup>rd</sup> vaccination within the timeframe of current analyses. The other patients (n=71) deferred the 3<sup>rd</sup> vaccination for personal reasons, most often because they felt they were sufficiently protected or they thought a 3<sup>rd</sup> vaccination would not be effective anyway. N: number of patients that did not receive a 3<sup>rd</sup> vaccination during the time under study.

eTable 3

	SARS-CoV-2 infection	
	Baseline, n (%)	Follow up, n (%)
<b>All patients</b>	24 (4.2)	22 (2.0)
<b>Lymphoma</b>		
During rituximab ± chemotherapy	1 (2.6)	1 (2.5)
<12mo after rituximab ± chemotherapy	0	1 (2.8)
<12mo after autologous HCT (BEAM)	0	0
<b>Multiple myeloma</b>		
1 <sup>st</sup> line therapy	1 (4.3)	2 (4.3)
Daratumumab	1 (2.3)	2 (2.3)
IMiDs	5 (10.9)	2 (2.2)
<9mo after autologous HCT (HDM)	5 (11.4)	1 (2.3)
<b>CLL</b>		
Watch & wait	0	3 (2.3)
Ibrutinib	2 (6.1)	1 (3.0)
<b>CML</b>		
Tyrosine kinase inhibitor	2 (4.8)	4 (2.4)
<b>AML and high-risk MDS</b>		
Hypomethylating therapy	0	0
High-dose chemotherapy	0	0
<b>Myeloproliferative disease</b>		
Ruxolitinib	2 (6.5)	0
<b>Allogeneic HCT</b>		
< 6 mo after HCT	1 (2.1)	2 (2.0)
Chronic GvHD	2 (4.3)	2 (2.0)

**Supplemental Table 3. SARS-CoV-2-infected patients.** Indicated are patients who had been SARS-CoV-2 infected prior to vaccination ('baseline') or became infected during follow up. Prior SARS-CoV-2 infection is defined as obtaining N IgG >14.3 BAU/ml at baseline or at any time during follow up. Mo: months.

CD19-directed

2 (4.8)

1 (2.3)

eTable 4

A

	All	IgG S1 after 2 <sup>nd</sup> vaccination (BAU/ml)			Time (days) <sup>1</sup>	IgG S1 after 3 <sup>rd</sup> vaccination (BAU/ml)			p-value		
	N	N	median	25th - 75th percentile	Median (range)	N	median	25th - 75th percentile	3 <sup>rd</sup> vs 2 <sup>nd</sup>		
<b>All patients</b>	27	25	443.1	31.4	3872.6	88 (1-140)	26	540.8	60.0	8819.0	0.19
<b>Autologous HCT</b>											
BEAM	2	2	0.1	0.1		33 (1-64)	2	59.5	1.4		0.18
HDM	14	13	562.6	130.8	3872.6	102 (30-140)	13	8498.5	1315.4	12576.3	0.02
Bu/Cy	1	1	139.5	139.5	139.5	103	1	11767.1	11767.1	11767.1	-
<b>Allogeneic HCT<sup>2</sup></b>	7	6	832.4	144.0	6379.8	65 (41-106)	7	73.5	49.0	109.2	0.05
<b>CAR T cell therapy</b>	3	3	0.1	0.1		92 (43-119)	3	0.3	0.1		0.65

B

	N	%	Autologous HCT	Allogeneic HCT	CAR T cell
<b>All patients</b>	27	4.6	17	7	3
<b>Lymphoma</b>					
During R-chemo	3	7.5	1	-	2
<12 months after R-chemo	1	2.8	1	-	-
<12 months after autologous HCT (BEAM)	1	4.0	-	-	1
<b>Multiple myeloma</b>					
1st line therapy	14	60.9	14	-	-
<b>Chronic lymphocytic leukemia</b>					
Ibrutinib	1	3.0	-	1	-
<b>Acute myeloid leukemia and high-risk MDS</b>					
Hypomethylating therapy	3	18.8	-	3	-
High-dose chemotherapie	4	22.2	1	3	-

**Supplemental Table 4: Characteristics of patients who received cell therapy after the 2<sup>nd</sup> mRNA-1273 vaccination.** **A.** Types of cell therapy received. <sup>1</sup>Time between cell therapy and 3<sup>rd</sup> vaccination. <sup>2</sup>All allogeneic HCT recipients received lymphocyte replete transplants with a haplo-identical donor (n=3; 2 unvaccinated donors, 1 vaccinated), matched unrelated donor (n=3; vaccination status unknown) or cord blood donor (n=1). Six had GvHD prophylaxis (n=2) or GvHD therapy (n=4) at the time of 3<sup>rd</sup> vaccination, which consisted of a calcineurin inhibitor or sirolimus, mycophenolic acid and/or prednisolone. BEAM: carmustine, etoposide, cytarabine, melphalan; HDM: high dose melphalan; Bu/Cy; busulphan cyclophosphamide. **B.** Cohorts of which intercurrent cell therapy patients were from.